NEW YORK (GenomeWeb News) – Gen-Probe said after the close of the market on Tuesday that its board of directors has authorized the repurchase of up to $250 million of the firm’s common stock over the next two years.
 
The San Diego-based molecular diagnostics firm has roughly 54.2 million shares of common stock outstanding and has plenty of cash on hand to fund the buyback program. As of the end of June, Gen-Probe had $499.2 million in cash, cash equivalents, and short-term investments, as well as no debt.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

National Geographic reports that marine mammals have lost a gene that could make them more susceptible to organophosphate damage.

NPR reports on Human Cell Atlas Consortium's effort to catalog all the different cell types within the human body.

The Union of Concerned Scientists surveyed US government scientists about Trump Administration policies and more, Science reports.

In PNAS this week: history and genetic diversity of the scarlet macaw, approach for predicting human flu virus evolution, and more.